FR23C1001I2 - Composition de facteur vii - Google Patents

Composition de facteur vii

Info

Publication number
FR23C1001I2
FR23C1001I2 FR23C1001C FR23C1001C FR23C1001I2 FR 23C1001 I2 FR23C1001 I2 FR 23C1001I2 FR 23C1001 C FR23C1001 C FR 23C1001C FR 23C1001 C FR23C1001 C FR 23C1001C FR 23C1001 I2 FR23C1001 I2 FR 23C1001I2
Authority
FR
France
Prior art keywords
composition
factor vii
vii
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1001C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of FR23C1001I1 publication Critical patent/FR23C1001I1/fr
Application granted granted Critical
Publication of FR23C1001I2 publication Critical patent/FR23C1001I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FR23C1001C 2009-06-26 2023-01-10 Composition de facteur vii Active FR23C1001I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0954390A FR2947181B1 (fr) 2009-06-26 2009-06-26 Composition de facteur vii
EP10734272.7A EP2445516B1 (fr) 2009-06-26 2010-06-18 Composition de facteur vii
PCT/FR2010/051229 WO2010149907A1 (fr) 2009-06-26 2010-06-18 Composition de facteur vii

Publications (2)

Publication Number Publication Date
FR23C1001I1 FR23C1001I1 (fr) 2023-03-10
FR23C1001I2 true FR23C1001I2 (fr) 2025-03-28

Family

ID=41620211

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0954390A Active FR2947181B1 (fr) 2009-06-26 2009-06-26 Composition de facteur vii
FR23C1001C Active FR23C1001I2 (fr) 2009-06-26 2023-01-10 Composition de facteur vii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0954390A Active FR2947181B1 (fr) 2009-06-26 2009-06-26 Composition de facteur vii

Country Status (17)

Country Link
US (3) US9029316B2 (fr)
EP (2) EP2445516B1 (fr)
JP (3) JP5706888B2 (fr)
KR (1) KR101468115B1 (fr)
CN (2) CN105106943A (fr)
AR (1) AR077234A1 (fr)
AU (1) AU2010264369B2 (fr)
BR (1) BRPI1010707A2 (fr)
CA (1) CA2764779C (fr)
DK (2) DK2985033T6 (fr)
ES (2) ES2550269T3 (fr)
FR (2) FR2947181B1 (fr)
IL (1) IL216872A (fr)
NL (1) NL301213I2 (fr)
PL (2) PL2985033T3 (fr)
TR (1) TR201906145T4 (fr)
WO (1) WO2010149907A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004294403A1 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor VII solutions to remove virus
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
AU2011350895B2 (en) 2010-12-30 2015-05-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
EP2687595B1 (fr) * 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Procédé de purification de facteur VII transgénique
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
US20180169297A1 (en) 2015-06-12 2018-06-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Injectable composition of factor vii and fillers
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP4303228B1 (fr) 2016-07-11 2026-05-27 OPKO Biologics Ltd. Facteur vii de coagulation à action prolongée et procédés de production associés
FR3082427B1 (fr) 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
EP3833381B1 (fr) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Polypeptides de facteur vii modifiés pour une administration sous-cutanée
CN117860874B (zh) * 2024-03-12 2024-07-02 正大天晴药业集团南京顺欣制药有限公司 重组人凝血因子VIIa的药物组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
JP3543144B2 (ja) * 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
DE19538687A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
ATE264340T1 (de) * 1999-08-17 2004-04-15 Novo Nordisk Healthcare Ag Stabilisierung von gefriergetrocknetem kuchen
WO2001083725A1 (fr) * 2000-05-03 2001-11-08 Novo Nordisk A/S Variants du facteur vii humain de coagulation
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
JP4915918B2 (ja) * 2003-06-19 2012-04-11 バイエル ヘルスケア エルエルシー 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
EP1656158B1 (fr) * 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Composition pharmaceutique liquide aqueuse de polypeptides du facteur vii
US20090041747A1 (en) * 2005-02-24 2009-02-12 Novo Nordisk Health Care Ag Compounds for Stabilizing Factor VII Polypeptide Formulations
JP2008539208A (ja) * 2005-04-28 2008-11-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 活性化型のｖｉｉ因子ポリペプチドを含んでいる閉鎖容器、調製する方法、並びにキットおよび前記キットを使用する方法
US20090017007A1 (en) * 2005-08-26 2009-01-15 Maxygen Holdings Ltd. Liquid factor vii composition
FR2894831B1 (fr) * 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
WO2008078189A2 (fr) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Compositions de facteur vii et viia
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
ES2595059T3 (es) * 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
CN101674805A (zh) * 2007-05-02 2010-03-17 诺沃-诺迪斯克保健股份有限公司 包括芳香族防腐剂和抗氧化剂的高浓度因子ⅶ多肽制剂
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii

Also Published As

Publication number Publication date
PL2445516T3 (pl) 2015-12-31
BRPI1010707A2 (pt) 2016-03-15
US20120087908A1 (en) 2012-04-12
WO2010149907A1 (fr) 2010-12-29
EP2985033B3 (fr) 2022-10-26
CA2764779C (fr) 2015-09-29
US20160271233A1 (en) 2016-09-22
KR20120047918A (ko) 2012-05-14
CN102458455A (zh) 2012-05-16
CN105106943A (zh) 2015-12-02
DK2985033T3 (da) 2019-06-17
JP2012530770A (ja) 2012-12-06
AU2010264369B2 (en) 2013-06-27
IL216872A0 (en) 2012-02-29
AR077234A1 (es) 2011-08-10
US9358275B2 (en) 2016-06-07
AU2010264369A1 (en) 2012-01-19
IL216872A (en) 2017-07-31
US9968662B2 (en) 2018-05-15
EP2445516B1 (fr) 2015-08-12
CN102458455B (zh) 2015-04-08
NL301213I2 (nl) 2023-12-14
US9029316B2 (en) 2015-05-12
TR201906145T4 (tr) 2019-05-21
FR2947181B1 (fr) 2012-05-04
CA2764779A1 (fr) 2010-12-29
ES2550269T3 (es) 2015-11-05
EP2445516A1 (fr) 2012-05-02
US20150216951A1 (en) 2015-08-06
EP2985033A1 (fr) 2016-02-17
EP2985033B1 (fr) 2019-03-20
JP2017081978A (ja) 2017-05-18
FR2947181A1 (fr) 2010-12-31
ES2725449T3 (es) 2019-09-24
PL2985033T3 (pl) 2019-08-30
ES2725449T7 (es) 2022-12-20
NL301213I1 (fr) 2023-01-18
DK2985033T6 (da) 2022-11-07
FR23C1001I1 (fr) 2023-03-10
JP5706888B2 (ja) 2015-04-22
JP2015134795A (ja) 2015-07-27
KR101468115B1 (ko) 2014-12-03
DK2445516T3 (en) 2015-10-19

Similar Documents

Publication Publication Date Title
FR23C1001I1 (fr) Composition de facteur vii
SMT201600307B (it) Composizione liposomiale
BRPI1013588A2 (pt) composição
ME03475B (fr) Compositions antiparasitaires comprenant dihydroazoles
EP2515946A4 (fr) Nanoconjugués et compositions de nanoconjugués
BRPI1015474A2 (pt) composição
FR2942627B1 (fr) Composition de graisse
EP2488022A4 (fr) Compositions
EP2675909A4 (fr) Composition de glucosylstevia
BR112012005237A2 (pt) utilização de composições ternárias
EP2720561A4 (fr) Composition de stévia
EP2713762A4 (fr) Composition de stévia
BRPI1013335A2 (pt) composição compósita
EP2470605A4 (fr) Compositions durcies de polyhydroxyalcanoate
UY33161A (es) Composiciones plaguicidas
DOP2011000396A (es) Composiciones novedosas
BRPI1010690A2 (pt) composições
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
FI20096144A0 (fi) Ulkovalaisu
EP2429699A4 (fr) Modification de la densité
EP2474324A4 (fr) Composition de revêtement
PT2635269T (pt) Composição de combinação
DK2453858T3 (da) Fremgangsmåde
EP2494966A4 (fr) Composition stable de rasagiline
EP2479211A4 (fr) Composition de fluorocaoutchouc